Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8743545 | 0.86 | MEN1 (0.35) | MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL20213991 | 0.83 | KMT2A (0.36) | MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL20120334 | 0.83 | KMT2A (0.36) | MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL22436681 | 0.83 | MEN1 (0.41) | MEN1KMT2AL3MBTL1KDM4CNPC1 | |
| SCHEMBL30679074 | 0.83 | MEN1 (0.41) | MEN1KMT2AL3MBTL1KDM4CNPC1 | |
| SCHEMBL17678845 | 0.82 | MEN1 (0.34) | MEN1KMT2AL3MBTL1KDM4CNPC1 | |
| SCHEMBL3078865 | 0.81 | MEN1 (0.38) | MEN1KMT2AL3MBTL1KDM4CNPC1 | |
| SCHEMBL8572408 | 0.81 | MEN1 (0.37) | MEN1KMT2AL3MBTL1KDM4CNPC1 | |
| SCHEMBL6690970 | 0.80 | MEN1 (0.34) | MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL27098751 | 0.79 | MEN1 (0.33) | MEN1KMT2AL3MBTL1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| CN-119954801-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114867727-B | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-114867727-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3204391-B1 | BACE1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-08-29 | — | — | EP | disclosed |
| WO-2016055496-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055496-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102105-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | US | disclosed |
| US-20160102105-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | US | disclosed |
| US-20160102105-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | US | disclosed |
| US-5416076-A | S-adenosyl methionine decarboxylase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-05-16 | — | — | US | disclosed |
| US-5308837-A | 5'-amine substituted adenosine analogs as immunosuppressants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-05-03 | — | — | US | disclosed |
| EP-0472181-A2 | 5-Amine substituted adenosine analogs as immunosuppressants | MERRELL PHARMACEUTICALS INC. (US) | 1992-02-26 | — | — | EP | disclosed |
| EP-0358536-A2 | Novel S-adenosyl methionine decarboxylase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1990-03-14 | — | — | EP | disclosed |
| EP-0351475-A1 | S-Adenosylmethionine decarboxylase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | MEN1 1910/4885KMT2A 1588/4885L3MBTL1 1083/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | MEN1 1944/4885KMT2A 1250/4885L3MBTL1 1412/4885 |
| US-20160102105-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | MEN1 2769/4885KMT2A 2749/4885L3MBTL1 3525/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | MEN1 1910/4885KMT2A 1588/4885L3MBTL1 1083/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | MEN1 1955/4885KMT2A 767/4885L3MBTL1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.